US Bancorp DE Has $733,000 Stake in Glaukos Co. (NYSE:GKOS)

US Bancorp DE reduced its position in Glaukos Co. (NYSE:GKOS) by 3.7% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,629 shares of the medical instruments supplier’s stock after selling 218 shares during the quarter. US Bancorp DE’s holdings in Glaukos were worth $733,000 as of its most recent filing with the SEC.

Several other large investors also recently modified their holdings of the company. Point72 Asset Management L.P. bought a new stake in Glaukos during the second quarter valued at $67,460,000. Primecap Management Co. CA lifted its stake in shares of Glaukos by 43.9% in the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after purchasing an additional 372,180 shares during the period. Allspring Global Investments Holdings LLC boosted its position in shares of Glaukos by 148.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after purchasing an additional 246,322 shares in the last quarter. Iron Triangle Partners LP grew its stake in Glaukos by 75.6% during the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after purchasing an additional 184,919 shares during the period. Finally, Driehaus Capital Management LLC increased its holdings in Glaukos by 24.0% in the second quarter. Driehaus Capital Management LLC now owns 803,650 shares of the medical instruments supplier’s stock worth $95,112,000 after purchasing an additional 155,653 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the company. Stifel Nicolaus increased their price target on Glaukos from $130.00 to $145.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Piper Sandler set a $140.00 target price on shares of Glaukos in a research report on Thursday, October 17th. Wells Fargo & Company raised their price target on shares of Glaukos from $135.00 to $145.00 and gave the stock an “overweight” rating in a report on Tuesday, November 5th. Needham & Company LLC upped their price objective on shares of Glaukos from $131.00 to $137.00 and gave the company a “buy” rating in a report on Thursday, August 1st. Finally, JPMorgan Chase & Co. increased their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. Four equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $134.55.

Insider Transactions at Glaukos

In other news, Director Marc Stapley sold 6,250 shares of the stock in a transaction that occurred on Thursday, August 15th. The shares were sold at an average price of $125.93, for a total transaction of $787,062.50. Following the completion of the transaction, the director now directly owns 34,076 shares of the company’s stock, valued at $4,291,190.68. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In related news, COO Joseph E. Gilliam sold 5,000 shares of the company’s stock in a transaction that occurred on Wednesday, August 21st. The shares were sold at an average price of $129.36, for a total transaction of $646,800.00. Following the sale, the chief operating officer now directly owns 102,169 shares in the company, valued at approximately $13,216,581.84. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Marc Stapley sold 6,250 shares of the firm’s stock in a transaction that occurred on Thursday, August 15th. The stock was sold at an average price of $125.93, for a total transaction of $787,062.50. Following the completion of the transaction, the director now directly owns 34,076 shares of the company’s stock, valued at approximately $4,291,190.68. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,525 shares of company stock worth $2,142,029 in the last 90 days. Insiders own 6.40% of the company’s stock.

Glaukos Stock Up 1.7 %

Shares of NYSE GKOS opened at $141.75 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.67. Glaukos Co. has a 1 year low of $59.22 and a 1 year high of $143.58. The stock has a market capitalization of $7.82 billion, a P/E ratio of -46.94 and a beta of 1.02. The company has a 50-day moving average price of $129.89 and a 200-day moving average price of $120.91.

Glaukos (NYSE:GKOS) last released its quarterly earnings results on Monday, November 4th. The medical instruments supplier reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.20. Glaukos had a negative return on equity of 18.99% and a negative net margin of 42.43%. The business had revenue of $96.70 million during the quarter, compared to analyst estimates of $91.50 million. During the same period in the prior year, the firm posted ($0.50) EPS. Glaukos’s quarterly revenue was up 23.9% compared to the same quarter last year. On average, equities research analysts forecast that Glaukos Co. will post -1.98 EPS for the current fiscal year.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.